Directorate Changes | 26-Oct-2022 | 07:00 | RNS |
Second Price Monitoring Extn | 25-Oct-2022 | 16:42 | RNS |
Price Monitoring Extension | 25-Oct-2022 | 16:37 | RNS |
Second Price Monitoring Extn | 25-Oct-2022 | 14:05 | RNS |
Price Monitoring Extension | 25-Oct-2022 | 14:00 | RNS |
Second Price Monitoring Extn | 25-Oct-2022 | 11:05 | RNS |
Price Monitoring Extension | 25-Oct-2022 | 11:00 | RNS |
Signs Commercial License Agreement with Genmab | 25-Oct-2022 | 07:00 | RNS |
Change of Nominated Adviser | 13-Oct-2022 | 07:00 | RNS |
Holding(s) in Company | 28-Sep-2022 | 12:31 | RNS |
Preclinical data at the EuroMAbNet Annual Meeting | 23-Sep-2022 | 07:00 | RNS |
Change of Registered Office | 06-Sep-2022 | 12:54 | RNS |
First patient dosed in Cohort 2 of the ModiFY | 16-Aug-2022 | 14:00 | RNS |
Scancell to produce TCB antibodies | 23-Jun-2022 | 07:00 | RNS |
Second Price Monitoring Extn | 15-Jun-2022 | 14:06 | RNS |
Currency | UK Pounds |
Share Price | 14.50p |
Change Today | -0.50p |
% Change | -3.33 % |
52 Week High | 19.50 |
52 Week Low | 8.92 |
Volume | 342,999 |
Shares Issued | 927.98m |
Market Cap | £134.56m |
Beta | 0.00 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
16:25 | 20,000 @ 14.11p |
16:12 | 4,846 @ 14.11p |
16:04 | 66 @ 15.00p |
15:58 | 169 @ 14.79p |
15:57 | 2,677 @ 14.79p |
CEO | Lindy Durrant |
CFO | Sath Nirmalananthan |
You are here: research